Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
5(100.0%)
5Total
Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03322865Phase 2Active Not Recruiting

Obinutuzumab in Marginal Zone Lymphoma

Role: collaborator

NCT03474744Phase 2Active Not Recruiting

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

Role: collaborator

NCT05099471Phase 2Recruiting

Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia

Role: collaborator

NCT04268277Phase 2Terminated

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Role: collaborator

NCT03620903Phase 2Active Not Recruiting

Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

Role: collaborator

All 5 trials loaded